Home
>
National Drug Code (NDC)
>
Pentazocine Hydrochloride and Naloxone Hydrochloride
Pentazocine Hydrochloride and Naloxone Hydrochloride - 43386-680-01 - (Pentazocine Hydrochloride and Naloxone Hydrochloride)
Drug Information of Pentazocine Hydrochloride and Naloxone Hydrochloride
| Product NDC: | 43386-680 |
| Proprietary Name: | Pentazocine Hydrochloride and Naloxone Hydrochloride |
| Non Proprietary Name: | Pentazocine Hydrochloride and Naloxone Hydrochloride |
| Active Ingredient(s): | .5; 50 mg/1; mg/1 & nbsp; Pentazocine Hydrochloride and Naloxone Hydrochloride |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Pentazocine Hydrochloride and Naloxone Hydrochloride
| Product NDC: | 43386-680 |
| Labeler Name: | GAVIS Pharmaceuticals, LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA075735 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20110511 |
Package Information of Pentazocine Hydrochloride and Naloxone Hydrochloride
| Package NDC: | 43386-680-01 |
| Package Description: | 100 TABLET in 1 BOTTLE (43386-680-01) |
NDC Information of Pentazocine Hydrochloride and Naloxone Hydrochloride
| NDC Code | 43386-680-01 |
| Proprietary Name | Pentazocine Hydrochloride and Naloxone Hydrochloride |
| Package Description | 100 TABLET in 1 BOTTLE (43386-680-01) |
| Product NDC | 43386-680 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Pentazocine Hydrochloride and Naloxone Hydrochloride |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20110511 |
| Marketing Category Name | ANDA |
| Labeler Name | GAVIS Pharmaceuticals, LLC |
| Substance Name | NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE |
| Strength Number | .5; 50 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Competitive Opioid Antagonists [MoA],Partial Opioid Agonist/Antagonist [EPC],Partial Opioid Agonists [MoA],Opioid Antagonist [EPC],Opioid Antagonists [MoA] |
